Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals displays a strong growth trajectory, particularly with Dupixent, which is projected to achieve approximately $21 billion in peak U.S. sales by 2030, bolstered by expansions into new indications. The collaboration with Sanofi is poised to enhance profitability, with anticipated revenue increases from this partnership expected to contribute an additional $1 billion by 2027, as development costs are cleared by the third quarter of 2026. Furthermore, Regeneron's diversified pipeline, including successful Phase III trials in allergy programs and ongoing developments in oncology and neurology, positions the company for sustained revenue growth beyond its existing core franchises.

Regeneron Pharmaceuticals faces a challenging outlook primarily due to declining sales of its flagship product, EYLEA, which are impacted by the emergence of biosimilars and a slow transition to the newer formulation, EYLEA HD. The company's development pipeline, which includes multiple programs in competition, is at risk of failing to meet regulatory expectations or achieving commercial success, potentially leading to lower future revenues and a diminished ability to execute on growth strategies. Additionally, the performance of key products like Dupixent and Libtayo may fall short of investor expectations, further contributing to the negative sentiment surrounding the company's long-term financial prospects.